

Krishnan Ramaswamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7607387/publications.pdf>

Version: 2024-02-01

8
papers

182
citations

1684188
5
h-index

1588992
8
g-index

10
all docs

10
docs citations

10
times ranked

387
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	10.7	90
2	Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2019, 37, 212-212.	1.6	30
3	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	3.9	28
4	Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 524-530.	3.9	14
5	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <i>Advances in Therapy</i> , 2020, 37, 2083-2097.	2.9	12
6	Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 889-897.	0.9	4
7	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	2
8	PD15-11â€fSURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE. <i>Journal of Urology</i> , 2019, 201, .	0.4	1